Mark Heinen - Mar 31, 2022 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role
Head of Finance and interim Chief Financial Officer
Signature
/s/ Mark Heinen
Stock symbol
BTTX
Transactions as of
Mar 31, 2022
Transactions value $
$9,900
Form type
4
Date filed
4/4/2022, 04:28 PM
Previous filing
Dec 15, 2021
Next filing
Jun 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock Purchase $9.9K +5K +50% $1.98 15K Mar 31, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTTX Stock Option (Right to Buy) Award $0 +32.8K $0.00 32.8K Apr 1, 2022 Common Stock 32.8K $1.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/4 of the shares subject to the stock option on April 1, 2023 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on April 1, 2022.

Remarks:

Head of Finance and interim Chief Financial Officer